Weight-Loss drug tirzepatide may help keep heart rhythm steady after ablation

NCT ID NCT07382024

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This trial tests whether tirzepatide, a drug used for diabetes and weight loss, can reduce the return of atrial fibrillation (AFib) after a heart procedure called catheter ablation. Overweight or obese adults with persistent AFib will receive either tirzepatide injections plus standard care, or standard care alone. The main goal is to see if the drug lowers the amount of time spent in AFib three months after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Tirzepatide
What this could lead to
If it works, this could point toward a way to lower the chance of AFib returning after ablation and improve weight and metabolic health.
What could go wrong
This is a small, early-phase trial with only 200 participants. The drug may not reduce AFib burden, and side effects like nausea or digestive issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION ABLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Taiwan University Hospital Cardiovascular Center

    Taipei, 100, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.